Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03357120 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA After Neoadjuvant Chemotherapy

Study acronym: ALIENOR
StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 120 participants (planned 180)
    • Primary completion date changed from estimate of Oct 2026 to Mar 10, 2022
    • Study completion date changed from estimate of Oct 2028 to Apr 16, 2025
    • Eligibility criteria expanded, about 24 words
    • Site details revised
  2. Primary completion date: Oct 2022 to Oct 2026
    • Study completion date: Oct 2024 to Oct 2028
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Bergonié
40 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological response.
Trial Details
NCT Number NCT03357120
Lead Sponsor Institut Bergonié
Collaborators: Fondation Bergonié
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov